Duration

As interest rates surge: flighty deposits and lending

Retrieved on: 
Friday, April 5, 2024
Neumark, Face, BCBS, Quarterly Journal of Economics, COVID-19, Cash, MRO, Intensive word form, Duration, Disclosure, The, Return, Bank statement, DFR, Research Papers in Economics, Investment, DEP, Federal, Prudential, CEMFI, Core, Synthetic control method, Interest rate risk, Journal of Political Economy, Policy, OLS, Logic, PDF, LOAN, ECB, Risk, International, Shock, Quarterly Journal, ROA, Risk management, Panetta, HHS, T2, T3, E51, Silicon Valley Bank, Common, Social science, NBER, EBA, Propensity score matching, Control, JEL, University Challenge 2013–14, Database, Rigidity, Yb, Social Science Research Network, The Journal of Finance, Bednarek, Journal, Research, Public policy, AT1, Journal of Monetary Economics, PSM, Big data, McPhail, Literature, Medical classification, Federal Reserve, Robustness, Paper, NPL, Financial economics, Deposit account, European Central Bank, Gérard Schivardi, Remuneration, Central bank, Conference, Environment, Political economy, MDA, Equation, Collateral damage, Monetary economics, Monetary policy, Kernel, Hoffmann, Website, Movement, Reproduction, Financial intermediary, Silicon, FE, Working paper, Injection, American Economic Review, Data, G21, AnaCredit, Probability, Total, Lombard, Bank
Key Points: 

    ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

    Retrieved on: 
    Monday, February 26, 2024
    Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

    Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

    Key Points: 
    • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
    • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
    • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
    • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

    Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

    Retrieved on: 
    Monday, December 4, 2023
    Oncology, Professional Services, Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Symantec Endpoint Protection, Dor, NYSE, Safety, CANF, Rabin Medical Center, Treatment, RECIST, Duration, Disease, Liver cancer, RAS, Patient, Inflammation, Growth, PFS, Pharmacokinetics, DCR, Activity, Conference, ORR, Trial of the century, Survival, Phase, Cancer, Rated R, Progression-free survival, TASE, AACR, Pharmaceutical industry

    Can-Fite completed the protocol design of the CF102-222PC clinical study entitled: “A Phase II Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma”.

    Key Points: 
    • Can-Fite completed the protocol design of the CF102-222PC clinical study entitled: “A Phase II Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma”.
    • This is a multicenter open-label trial in patients with advanced pancreatic adenocarcinoma whose disease has progressed on at least 1st-line therapy or who refuse standard treatment.
    • The trial will evaluate the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson in this population.
    • “This Phase IIa study is designed as an open-label one, enabling us to assess the safety and potential efficacy of Namodenoson in pancreatic cancer patients whose disease has progressed despite first-line treatment.

    ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

    Retrieved on: 
    Friday, October 27, 2023
    Research, ORY, Fruit, DMC, Food, Deficit spending, Risk, Medicine, ECNP, Schizophrenia, Platinum, ICMJE recommendations, SCLC, Charcot–Marie–Tooth disease, Sciatic nerve, Psychotherapy, Paclitaxel, NET, FCCC, MRD, Safety, EVOLUTION, BPD, Kabuki syndrome, Patient, Borderline personality disorder, ALS, Fox Chase Cancer Center, Genomics, Human, Duration, Glomus tumor, Measure (mathematics), Clinical trial, Dor, DSM-IV codes, Animal, European College of Neuropsychopharmacology, LSD1, FMS, CMT, FDA, IND, Innovation, ISIN, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, HOPE, AML, Failure, Medical device, Pharmaceutical industry, Nursing, Cryptocurrency, EU, Science

    Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

    Key Points: 
    • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
    • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
    • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
    • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

    Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

    Retrieved on: 
    Monday, October 23, 2023
    IBS-C, Rat, Bloating, Patient, Abdominal pain, Constipation, American College, Incidence, Food, MPH, Diarrhea, RD, ACG, Post hoc analysis, Duration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American College of Gastroenterology, AS3, Death, Abdominal distension, Dehydration, Risk, Safety, Pain, Mayo Clinic, Human, Pharmaceutical industry, Birth control, CSBM, MD

    “Physicians and other professionals attending ACG 2023 work with IBS-C patients every day and know all too well how challenging this condition can be.

    Key Points: 
    • “Physicians and other professionals attending ACG 2023 work with IBS-C patients every day and know all too well how challenging this condition can be.
    • “While a significant proportion of patients will have an early positive response to IBSRELA treatment, patient response rates increase with continued therapy.
    • The researchers concluded that these patients experience a relatively quick onset of symptom relief under tenapanor treatment and that weekly response rates continued to increase with treatment duration.
    • IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

    NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

    Retrieved on: 
    Monday, October 23, 2023
    Survival, Patient, RT, ESMO, NBTXR3, MOS, Lymph, Head, PFS, MD, Monroe Dunaway Anderson, Doctor of Philosophy, Duration, CA19-9, Quality of life, NANO, Rated R, Chemoradiotherapy, Clinical trial, Pancreatic cancer, Oncology, University, Nanobiotix, Safety, European Society for Medical Oncology, Cancer, Progression-free survival, MD Anderson Cancer Center, OS, Diagnosis, Medical imaging, Residential care, Pharmaceutical industry, Euronext, LAPC

    PARIS and CAMBRIDGE, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced updated data from two presentations at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO).

    Key Points: 
    • The 5-year overall survival rate for patients with unresectable locally advanced pancreatic cancer (LAPC) remains less than 5%.
    • Normally, these patients receive the combination of cytotoxic chemotherapy followed by concurrent chemoradiation if no metastatic progression has occurred.
    • Innovative new treatments that might extend survival and avoid additional harmful side effects are an urgent unmet need for this patient population.
    • “With the Phase 1 study now complete, our focus is to ensure that we learn everything we can to anticipate the potential results of NANORAY-312.

    Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

    Retrieved on: 
    Monday, October 23, 2023
    ASX, MHC, Progression-free survival, PD-L1, NSCLC, Mini, ESMO, Symantec Endpoint Protection, TPS, DOR, MOS, Pembrolizumab, PFS, Merck, Duration, Rated R, Survival, Autoimmune disease, ORR, ICO, IMM, Cancer, Patient, Merck & Co., Network equipment provider, Pharmaceutical industry

    SYDNEY, AUSTRALIA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces excellent new clinical data from the TACTI-002 / KEYNOTE-798 Phase II trial evaluating eftilagimod alpha (“efti”), a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment for patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC).

    Key Points: 
    • A significant overall survival benefit was achieved, with a 35.5-month median Overall Survival (mOS) in patients with TPS ≥1%, 23.4-month mOS in TPS 1-49%, and mOS not yet reached in TPS ≥50%.
    • Exceptional durability and quality of responses are increasingly evident with strong overall survival (OS) and progression free survival (PFS) rates across patients expressing PD-L1.
    • The 12-month PFS rates are 46.8%, 42.1%, and 55.0% for TPS >1%, TPS 1-49%, and TPS >50%, respectively.
    • Table 1: Overall Survival of Efti + KEYTRUDA® versus standard-of-care IO, IO-IO, IO-chemo, and IO-IO-chemo

    Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting

    Retrieved on: 
    Wednesday, October 25, 2023
    Luxury, Women, Clinical Trials, Health, Cosmetics, Consumer, Pharmaceutical, General Health, Retail, ASDS, Safety, 113 East Roosevelt (Phase II), Duration, Society, Pharmaceutical industry

    Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D.

    Key Points: 
    • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D.
    • will present final results from the Phase 2 study evaluating the safety, efficacy and duration of effect of 40U PrabotulinumtoxinA-xvfs at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago during an independent medical education session.
    • Title: A Phase II, Randomized, Double Blind, Active-Controlled, Increasing Dose Trial to Study the Safety and Duration of Effect of 40U PrabotulinumtoxinA-xvfs in Glabellar Lines: Final Results
      Time: 4:30 to 5:30 pm CT, Friday, November 3, 2023

    Zhongchao Inc. Introduces PRO-Based Disease Management Model for Lung Cancer Patients

    Retrieved on: 
    Monday, September 25, 2023
    Rapid response system, Depression, Duration, Anxiety, PRO, Cancer, Lung cancer, Appetite, App Store (iOS/iPadOS), American Journal of Clinical Oncology, WeChat, Patient, Nausea, Patient-reported outcome, Health, Fatigue, Medical imaging, Wu Zhongchao

    This model is geared toward aiding the recovery of lung cancer patients and enhancing their life quality.

    Key Points: 
    • This model is geared toward aiding the recovery of lung cancer patients and enhancing their life quality.
    • Zhongchao's existing patient management services already features a comprehensive range of offerings for lung cancer patients.
    • Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, "We believe that PRO-based symptom management method provides an invaluable way to detect lung cancer patients' underlying health issues accurately and comprehensively, assist clinical decisions and improve the quality of care for our lung cancer patients.
    • At Zhongchao, we are continually refining our approaches to patient management services, aiming to achieve meaningful and lasting impacts on the lives of cancer patients."

    $34.81 Bn Health Coaching Market - Global Opportunity Analysis and Industry Forecast, 2021-2022 & 2023-2031: Chronic Disease Prevalence and Online Coaching Spearheading Growth - ResearchAndMarkets.com

    Retrieved on: 
    Wednesday, September 13, 2023
    Health, Lifestyle, Telemedicine, Virtual Medicine, Consumer, Obesity, Duration, Prevalence, Diabetes, Office of Inspector General, U.S. Department of Health and Human Services, Weight loss, American Council, Government, Hypertension, Developed country, Post-traumatic stress disorder, Patient, Porter's five forces analysis, Veterans' affairs, Conditional sentence, Growth, U.S. Department of Veterans Affairs, Office of Inspector General, Benchmarking, Smoking cessation, Mental health, Behavior, Pharmaceutical industry, Nursing, Marketing, Tutoring, Exercise

    The "Health Coaching Market By Type, By Mode, By Duration, By Application: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

    Key Points: 
    • The "Health Coaching Market By Type, By Mode, By Duration, By Application: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
    • Health coaching is a type of lifestyle coaching that focuses on helping people improve their overall health and well-being through lifestyle and behavior changes.
    • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the health coaching market analysis from 2021 to 2031 to identify the prevailing health coaching market opportunities.
    • The report includes the analysis of the regional as well as global health coaching market trends, key players, market segments, application areas, and market growth strategies.